Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.86 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9440214 | 1.00 | HTR7 (0.86) | HTR7NPC1RAB9AHSD17B3GAA | |
| SCHEMBL5178977 | 0.98 | HTR7 (0.89) | HTR7NPC1RAB9AHSD17B3GAA | |
| SCHEMBL19757424 | 0.95 | HTR7 (0.77) | HTR7NPC1RAB9AHSD17B3GAA | |
| SCHEMBL7885389 | 0.92 | HTR7 (1.00) | HTR7NPC1RAB9AHSD17B3GAA | |
| SCHEMBL3424496 | 0.90 | NPC1 (0.87) | HTR7NPC1RAB9AHSD17B3TSHR | |
| SCHEMBL9680984 | 0.90 | NPC1 (0.87) | HTR7NPC1RAB9AHSD17B3TSHR | |
| SCHEMBL1040636 | 0.90 | NPC1 (0.87) | HTR7NPC1RAB9AHSD17B3TSHR | |
| SCHEMBL13085847 | 0.90 | HSD17B3 (0.85) | HTR7HSD17B3THRATHRBSTS | |
| SCHEMBL13085794 | 0.90 | HSD17B3 (0.85) | HTR7HSD17B3THRATHRBSTS | |
| SCHEMBL9680520 | 0.88 | NPC1 (0.91) | HTR7NPC1RAB9AHSD17B3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | HTR7 844/4885NPC1 4686/4885RAB9A 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.